Abstract
Background and objective: Salmeterol and fluticasone propionate are well established in the treatment of childhood asthma, and their combination is effective in children aged 4–11 years. Asthma guidelines recommend that the inhaler device best suited to the individual should be used to administer asthma treatment. The aim of this study was to further evaluate the efficacy of salmeterol/ fluticasone propionate combination (SFC) delivered by the Diskus™ (50/l00μg, one inhalation twice daily) and compare it with that observed when SFC is delivered by a chlorofluorocarbon-free pressurised metered-dose inhaler (pMDI) [25/50μg, two inhalations twice daily] in children aged 4–11 years with persistent asthma.
Patients and methods: This equivalence study had a multicentre, randomised, double-blind, double-dummy, parallel-group design and comprised asthmatic children aged 4–11 years who required beclometasone (beclomethasone dipropionate) ≤500 μg/day (or equivalent). After a 2-week run-in using existing inhaled corticosteroid therapy, patients were randomised to receive SFC via Diskus™ (n = 213) or pMDI (n = 215, with 82% using a spacer) for 12 weeks. Salbutamol (Ventolin®) was provided for symptomatic relief. The primary endpoint was mean morning peak expiratory flow rate (PEF) recorded by patients during weeks 1–12. Secondary endpoints included other lung function parameters, day- and night-time symptoms, use of rescue medication and percentage of symptom- and salbutamol-free days. Adverse events and 12-hour overnight urinary cortisol concentrations were monitored to assess safety.
Results: Treatment with SFC, delivered by either device, was highly effective in improving patients’ morning PEF and asthma symptoms. Over the whole study period, morning PEF (mean ± standard error) improved by 37.7 ± 3.1 L/min in the Diskus™ group and by 38.6 ± 3.0 L/min in the pMDI group. The −0.9 L/min difference between groups (95% CI −7.1, 5.4) was within the predefined criterion for equivalence of (i.e. −15, 15 L/min). The median percentage of symptom-free and rescue medication-free days and nights increased considerably in both groups. For all efficacy parameters assessed, improvement occurred for all age groups as early as weeks 1–4, and was sustained over the 12 weeks. Both Diskus™ and pMDI treatments were well tolerated and their safety profiles were comparable.
Conclusion: SFC delivered via Diskus™ or pMDI was shown to be highly effective in asthmatic children aged 4–11 years. Children as young as 4 years were able to use the Diskus™ and pMDI effectively. The combination is clinically equivalent when administered via either device in this patient population. This means that both Diskus™ and pMDI (+ spacer) are suitable for administration of SFC, which provides prescribers/users with a choice of device.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
GINA. Global strategy for asthma management and prevention. Bethesda (MD): National Institutes of Health (National Heart, Lung, and Blood Institute); 2002. Publication No. 02-3659
The International Study of Asthma and Allergies in Childhood. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. Lancet 1998; 351: 1225–32
Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481–8
Greening A, Ind P, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219–24
Condemi J, Goldstein S, Kalberg C, et al. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol 1999; 82: 383–9
Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 2000; 60: 1207–33
Bateman E, Britton M, Carrillo J, et al. Salmeterol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Invest 1998; 16: 193–201
Chapman K, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250μg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999; 6: 45–51
Aubier M, Pieters W, Schlosser N, et al. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93: 876–84
Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 150: 1108–16
Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527–34
Ringdal N, Eliraz A, Pruzinec R, et al. The salmeterol/fluticasone combination is more effective than fluticasone propionate plus oral montelukast in asthma. Respir Med 2003; 97: 234–41
Jenkins L, Woolcock A, Saarelainen P, et al. Salmeterol/ fluticasone propionate combination therapy 50/250μg twice daily is more effective than budesonide 800μg twice daily in treating moderate to severe asthma. Respir Med 2000; 94: 715–23
NIH. Highlights of the expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health (National Heart, Lung, and Blood Institute); 1997. Publication No. 97-4051A. 1-50
BTS. British guideline on the management of asthma. Thorax 2003; 58 Suppl. 1: 1–94
Busse W, Koenig S, Oppenheimer J, et al. Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol 2003; 111: 57–65
Chauhan S, Gogtay J. Aerosol delivery systems in childhood asthma. Indian J Pediatr 2001; 68 Suppl. 4: S17–22
Nielsen K, Auk I, Bojsen K, et al. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Eur Respir J 1998; 11: 350–4
Malton A, Sumby B, Dandiker Y. A comparison of in-vitro drug delivery from salbutamol Diskus and terbutaline Turbohaler inhalers. J Pharm Med 1996; 6: 35–48
Van den Berg N, Ossip M, Hederos C, et al. Salmeterol/ fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Pediatr Pulmonol 2000; 30: 97–105
Jones B, Jarvis P, Lewis J, et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313: 36–9
Davies N, Feddah M, Brown K, et al. In vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorti-coid products: influence of inspiratory flow rates. J Pharm Pharm Sci 2000; 3: 318–24
Newman S. Spacer devices for metered dose inhalers. Clin Pharmacokinet 2004; 43: 349–60
Acknowledgements
Funding for this study was provided by GlaxoSmithKline Research & Development (UK).
The authors thank the following investigators who took part in this study: Dr U Putnik, Dr M Vasar (Estonia); Dr E Billard, Dr A Chace, Dr M Epstein, Dr A Jahiel, Dr M Lafourcade, Dr J Mathieu, Dr D Ortolan, Dr J Robert (France); Dr U Behre, Dr H Bresser, Dr F Drobnitzky, Dr F Friedrichs, Dr R Gall, Dr H Generlich, Dr W Kamin, Dr K Kirsten, Dr U Klettke, Dr K Krause, Dr P Soemantri, Dr A Von Berg (Germany); Dr V Adamovica, Dr I Budrevica, Dr I Cirule (Latvia); Dr R Emuzyte, Dr J Kudzyte (Lithuania); Dr H Brackel, Dr S Gans, Dr R Van Gent, Dr J Hoekx, Dr K Illy, Dr P Overberg, Dr W Van der Toom, Dr A Widdershoven (The Netherlands); Dr B Andersen, Dr D Bjaamer, Dr K Iversen, Dr O Moe, DrL Rolfsjord, Dr K Sivertsen (Norway); Prof. R Kurzawa, Dr T Malaczynska, Prof. J Pietrzyk, Dr A Slomka, Dr G Wykretowicz (Poland); Dr N Barroso, Dr A Escribano, Dr G Hernandez, Dr C Cordero (Spain); Dr M Ingemansson, Dr T Jakobsson, Dr K Oberg, Dr S Orjestad, Dr I Strannegard, Dr I Winnergard (Sweden); Dr M Clamp, Dr J Courtney, Dr A Darrah, Dr J Dunn, Dr C Fletcher, Dr B Glancy, Dr K Gruffyyd-Jones, Dr R Lal-Sarin, Dr I Swan (UK).
Drs Godwood and Balsara are employees of GlaxoSmithKline Reasearch & Development (UK); the other authors have no potential conflicts of interest that are directly relevant to the contents of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bracamonte, T., Schauer, U., Emeryk, A. et al. Efficacy and Safety of Salmeterol/Fluticasone Propionate Combination Delivered by the Diskus™ or Pressurised Metered-Dose Inhaler in Children with Asthma. Clin. Drug Investig. 25, 1–11 (2005). https://doi.org/10.2165/00044011-200525010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200525010-00001